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Abstract 
Science benefits from criticism. We support the right of colleagues to criticise our work, as Mitchell 
has done in his commentary on the PACE trial of therapies for people with chronic fatigue syndrome 
(CFS), which we led.  However we also believe that criticism is only useful if it is based on an accurate 
account of such work.  In our view, Mitchell’s criticisms are, not based on an accurate account of the 
research. We address the main criticisms and conclude that both graded exercise therapy (GET) and 
cognitive behaviour therapy (CBT) are useful and safe treatments for people with CFS.  
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In his recent article, Mitchell has made a number of criticisms of the PACE trial (Mitchell, 2017). 
However, the criticisms are based on inaccurate information and are consequently misleading. 
1. Mitchell suggested that a re-analysis of some of the data related to the PACE trial found the effect 
sizes to be smaller than those which we originally reported (White et al, 2011). This is incorrect. He 
has confused the effect size reported in the main trial paper (which was calculated using scores of 
the two primary outcomes) with results of a secondary analysis of the data. The latter reports the 
proportions of participants meeting various criteria for recovery (see below) (White et al, 2013, 
Wilshire et al, 2017). 
2. Mitchell implies that we only released certain results, such as objective metrics from the 6-minute 
walking test data, as a consequence of data release that was forced upon us following an 
Information Tribunal in 2016 (Mitchell, 2017). These results were in fact published in our main 
results paper five years earlier (White et al, 2011).  
3. Mitchell states: “…it is also alleged that the investigators (perhaps inadvertently) influenced 
participants’ self-reports with indiscriminate encouragement in newsletters sent out during the trial” 
(Mitchell, 2017). It has indeed been alleged, but the allegation is incorrect.  As in all well-run trials, 
we engaged with participants by sending them regular newsletters about trial progress. As part of 
that, we included quotations of positive feedback about the trial and the treatments that they had 
received. The newsletters (which readers can review at 
http://www.wolfson.qmul.ac.uk/images/pdfs/participantsnewsletter3.pdf) did not name any 
treatment and included positive quotations about all four treatments being evaluated in the trial. 
We also measured participant expectation of their allocated treatment after they had been informed 
of it and, as reported in the main paper, most participants considered adaptive pacing therapy (APT) 
and GET to be most likely to help them, whereas the trial found CBT and GET were most effective 
(White et al, 2011).   
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4. Mitchell says “It is also alleged that the investigators switched their own scoring methods mid-
trial” (Mitchell, 2017). As is common practice in most trials, and as we agreed to do in our original 
protocol (White et al, 2007), the outline analysis plan was reviewed and a detailed analysis plan was 
written and subsequently published (Walwyn et al, 2013). This was approved by two independent 
oversight committees before any outcome data was analysed. The detailed plan used the same 
primary outcomes. The change Mitchell is referring to was in the scoring method of one of the 
primary outcome measures. A binary (0,0,1,1) scoring method was changed to a Likert scoring 
method (0,1,2,3), in order to provide a more accurate measure of efficacy. This change and the 
reason for it were clearly reported in the papers (White et al, 2011; Walwyn et al, 2013). Re-
analysing the data using the binary scoring made no difference to our conclusions that both CBT and 
GET are effective treatments (Goldsmith et al, 2016).  
5. Mitchell criticises us and one of our Universities for not releasing more data and earlier. This 
criticism is misleading. We have already explained that we simply did not have participants’ consent 
to release their individual patient date (White et al, 2016). This is because the public release of data, 
which has now occurred as a result of an Information Tribunal, and which Mitchell promotes in 
providing a link, has been explicitly proscribed by our Research Ethics Committee. We have however 
shared data with other researchers, including a Cochrane Collaboration team, who agreed to keep 
the data confidential.  
6. Finally, Mitchell suggests that a re-analysis of the proportions of participants meeting criteria for 
recovery suggest that few participants recovered with CBT and GET (Wilshire et al, 2017). We have 
already pointed out that our recovery (as opposed to improvement) estimates depended on 
assumptions (White et al, 2013; Sharpe et al, 2017). The Wiltshire reanalysis simply makes different 
assumptions, using more stringent thresholds to determine recovery. That having been said, our 
recovery rates were similar to those found in previous studies (22% recovered after CBT and GET) 
(Sharpe et al, 2017). 
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We agree with Mitchell that there are lessons to be learnt from the PACE trial, but they are not the  
lessons he suggests: 
1. Mitchell says: “First and foremost, it is imperative for researchers to publish studies in the 
most open and transparent manner possible.” In fact almost all our papers were published 
with open access, and we have responded to scientific queries and criticisms appropriately 
and repeatedly in papers cited here, in journal correspondence, and in over one hundred 
frequently asked questions available on the trial website 
(http://www.wolfson.qmul.ac.uk/current-projects/pace-trial). We have also shared data 
when ethically possible (White et al, 2016). 
2. Mitchell says: “A second lesson is that clinicians and researchers should work more closely 
with patients…”  In fact a patient charity and a patient were involved early on in designing 
the trial, and were full members of our trial steering and/or trial management committees 
(White et al, 2015).  
Mitchell says: “The third lesson is that, to promote acceptability, psychosocial treatments should be 
integrated into medical care.” In fact the PACE trial treatments were integrated with medical care 
and all participants in the PACE trial received appropriate medical care provided by CFS specialists. 
We suggest that the most obvious lesson from our experience of the PACE trial is that science can 
sometimes provide answers to questions that are not popular with everyone (Lancet, 2011; Hawkes, 
2011, Wessely, 2015, Sharpe et al, 2016). However such answers should stand or fall by independent 
replication, not by unreasonable criticism and demands for retraction. We note that the PACE trial 
replicated findings from many earlier randomised controlled trials, many of which were conducted 
by researchers in different countries (Castell et al 2011; Larun et al 2016). We look forward to 
further robust studies that the conclusion of the PACE trial that CBT and GET are superior to pacing 
and specialist medical care alone in improving both fatigue and physical functioning in patients with 
CFS.  
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